BioSpace News Archive

Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company, today reported financial results for the quarter and full year ended December 31, 2019 and summarized recent business results. “

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announced that a pre-emergency use authorization (EUA) application for NUZYRA• (omadacycline) has been submitted to the U.S. Food and Drug Administration (FDA).

Aptose Biosciences Inc. today announced financial results for the year and three months ended December 31, 2019 and reported on corporate developments.

PPD, Inc. (Nasdaq:PPD) today announced the cancellation of its fireside chat and related webcast at the Barclays Global Healthcare Conference, previously scheduled for Wednesday, March 11, at 11:45 a.m. (U.S. Eastern Time), as a result of the conference switching to a virtual format. About PPD PPD is a leading global contract research organization providing comprehensive, integrated drug development, labora

DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported business and financial results for the quarter and year ended December 31, 2019 and provided a corporate update. Recent Corporate Updates In January 2020, the Company contracted with a regional health plan to make its gene expression-based Pigment

22nd Century Group, Inc. announced the appointment of Lisa Parks as its Vice President of Acquisitions and Mei Kuo as its new Director of Communications and Investor Relations.

Clinical data presented at 2019 American Society of Hematology (ASH) annual meeting suggested that CPI-0610 could offer meaningful benefits beyond standard of care in myelofibrosis In addition to previously expanded MANIFEST Cohorts 3 and 2A, now expanding Cohort 1A Planning update for MANIFEST and discussions with regulatory agencies about CPI-0610 around mid-year, additional MANIFEST update before yearend

-- Unique combination of pharmacogenetic information with sophisticated, EMR-integrated software has been shown to reduce risk and improve outcomes --

Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced its financial results for the fourth quarter and twelve months ended December 31, 2019.

Following Series of US and European Patent Grants, Cellectis Strengthens its Intellectual Property on CRISPR-Edited T-cell Therapies